# Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

> **NCT02031055** · PHASE1 · COMPLETED · sponsor: **Taiho Oncology, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TAS-102 with a light tracer dose of [14C]FTD
- **DRUG:** TAS-102 with a light tracer dose of [14C] TPI
- **DRUG:** TAS-102 tablets

## Key facts

- **NCT ID:** NCT02031055
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-11
- **Final completion:** 2015-06-17
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02031055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02031055, "Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02031055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*